Browsing Tag
Lazard
14 posts
Oxylabs bets $3.6bn valuation on agentic AI web data infrastructure thesis
Warburg Pincus injects $130 million into Oxylabs at a $3.6 billion valuation, but can agentic AI data infrastructure defend that private-market benchmark?
MasTec’s $1.65bn Superior deal targets the electrical bottleneck behind AI data centres
MasTec’s acquisition of Superior Group expands the contractor from grid and fibre connections into the complex electrical systems inside hyperscale AI data centres.
Victoria PLC (AIM: VCP) holds refinancing rally as £300m debt cut tests flooring recovery
Victoria’s refinancing could cut liabilities by £300m and finance costs by £34m. Investors now need proof that flooring recovery can follow.
Beazley (LSE: BEZ) edges up 0.04% on Friday with Zurich scheme on glide path to court sanction and H2 completion
Beazley shareholders voted 99.9% in favour. Zurich keeps buying at 1,280p. The court hearing is next. The 2.3% arbitrage spread is the last word on this deal.
Lincoln International IPO: Why the $421m listing could test Wall Street’s appetite for boutique advisory firms
Advisory fees are recovering, but IPO investors want durability. Lincoln International’s LCLN listing tests Wall Street’s boutique bank appetite.
SoundHound AI bets on enterprise AI consolidation with LivePerson deal as SOUN trades near 52-week lows
SoundHound AI to acquire LivePerson in an all-stock deal targeting a $500M revenue opportunity. What the $250M enterprise value transaction means for SOUN investors and enterprise AI. Read more.
Rogo expands financial AI platform with Offset acquisition to automate spreadsheet-driven finance work
Rogo acquires Offset to bring AI agents directly into financial workflows used by banks and private equity firms. Discover what this shift could mean for finance.
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
Can NCC Group thrive without Escode? Inside the £275m pivot to Cyber
NCC to sell Escode to TDR Capital for £275M to focus on cybersecurity. Find out what this means for strategy, margins, and investor returns.
KKR and Stonepeak launch £1.6bn bid to take Assura private via scheme of arrangement
Find out how KKR and Stonepeak plan to reshape UK healthcare infrastructure through a £1.6B buyout of FTSE 250 REIT Assura plc.